Conclusion: The addition of raltegravir to stabilized patients receiving buprenorphine/naloxone does not significantly affect buprenorphine/naloxone or raltegravir pharmacokinetic or pharmacodynamic parameters.
PMID: 23421567 [PubMed – in process] (Source: The American Journal of Drug and Alcohol Abuse)
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment.
Call 1 (888) 460-6556 to speak with a counselor.
